BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38756663)

  • 1. KDM7A-DT induces genotoxic stress, tumorigenesis, and progression of p53 missense mutation-associated invasive breast cancer.
    Giannakakis A; Tsifintaris M; Gouzouasis V; Ow GS; Aau MY; Papp C; Ivshina AV; Kuznetsov VA
    Front Oncol; 2024; 14():1227151. PubMed ID: 38756663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good or not good: Role of miR-18a in cancer biology.
    Kolenda T; Guglas K; Kopczyńska M; Sobocińska J; Teresiak A; Bliźniak R; Lamperska K
    Rep Pract Oncol Radiother; 2020; 25(5):808-819. PubMed ID: 32884453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced immortalization,
    Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
    Gene X; 2020 Dec; 5():100030. PubMed ID: 32550556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsa_circ_002178 Promotes the Growth and Migration of Breast Cancer Cells and Maintains Cancer Stem-like Cell Properties Through Regulating miR-1258/KDM7A Axis.
    Li W; Yang X; Shi C; Zhou Z
    Cell Transplant; 2020; 29():963689720960174. PubMed ID: 32951449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.
    Meng Z; Liu Y; Wang J; Fan H; Fang H; Li S; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
    J Cell Physiol; 2020 Feb; 235(2):932-943. PubMed ID: 31236965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes.
    Mathias C; Muzzi JCD; Antunes BB; Gradia DF; Castro MAA; Carvalho de Oliveira J
    Front Oncol; 2021; 11():692170. PubMed ID: 34136413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
    Lo PK; Lee JS; Liang X; Sukumar S
    Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Ballot E; Galland L; Mananet H; Boidot R; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
    Breast Cancer Res; 2022 Nov; 24(1):80. PubMed ID: 36401316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
    Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
    Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
    Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
    Gene; 2020 Dec; 763S():100030. PubMed ID: 34493366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
    Song C; Shang F; Tu W; Liu X
    BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
    Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
    Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Jumonji Domain-Containing Histone Demethylase Homolog 1D/lysine Demethylase 7A (JHDM1D/KDM7A) Is an Epigenetic Activator of RHOJ Transcription in Breast Cancer Cells.
    Zhang Z; Chen B; Zhu Y; Zhang T; Zhang X; Yuan Y; Xu Y
    Front Cell Dev Biol; 2021; 9():664375. PubMed ID: 34249916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
    Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.
    Fredlund E; Staaf J; Rantala JK; Kallioniemi O; Borg A; Ringnér M
    Breast Cancer Res; 2012 Jul; 14(4):R113. PubMed ID: 22839103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.